Novartis's new heart failure drug to dominate with $1.9 billion global revenue by 2022, says GlobalData

21 June 2013

Following a launch scheduled for 2015 for the treatment of chronic heart failure (CHF), Swiss drug major Novartis’ (NOVN: VX) novel combination drug LCZ-696 will rapidly dominate the global CHF therapeutics sector and mark a drug development paradigm shift, says research and consulting firm GlobalData.

The firm’s latest report forecasts global sales of LCZ-696 to reach a massive $1.86 billion by 2022, with an estimated 15%-20% of all CHF patients across the USA and Europe treated with the drug by the end of the forecast period.

LCZ-696 expected to gain 55% share of US CHF market

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical